Mirati Therapeut Stock Price, News & Analysis

Mirati Therapeutics, Inc. (NASDAQ: MRTX) is a commercial stage biotechnology company focused on pioneering breakthrough therapies to transform the lives of patients with cancer. Specializing in molecularly targeted and immuno-oncology combination therapies, Mirati is at the forefront of cancer treatment innovation. The core of Mirati's mission is to develop drug candidates that target genetic and epigenetic drivers of cancer. The company leverages a strategic approach that includes selecting patients whose tumors depend on specific genetic alterations and employing a highly accomplished leadership team in oncology precision medicine.

Mirati Therapeutics is advancing three primary drug candidates through clinical development for multiple oncology indications. Their flagship product, KRAZATI® (adagrasib), has shown promising results in treating non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation. Adagrasib offers potential best-in-class efficacy, particularly for patients with central nervous system metastases. Notably, the drug has been granted conditional marketing authorization by the UK's MHRA and the European Commission, highlighting its impactful role in current cancer treatment paradigms.

Mirati's innovative pipeline also includes MRTX1719, a PRMT5 inhibitor, and MRTX1133, a selective KRASG12D inhibitor, both of which are designed to address high unmet medical needs. The company recently completed an upsized public offering, extending its cash runway to support upcoming milestones.

In recent developments, Mirati announced that Laurie Stelzer, Chief Financial Officer, will depart the company in September 2023, with Aaron Ondrey stepping in as interim CFO. This transition comes at a pivotal time as Mirati continues to advance its clinical programs and prepare for potential new product launches.

With a relentless focus on patient outcomes, Mirati's vision is to unlock the science behind a life beyond cancer. The company continues to collaborate with global healthcare regulators and partners to ensure broad access to its groundbreaking therapies.